2. Search Result
Search Result
Results for "

human CGRP receptor

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

8

Peptides

2

Inhibitory Antibodies

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10095
    Olcegepant
    Maximum Cited Publications
    42 Publications Verification

    BIBN-4096; BIBN 4096BS

    		 CGRP Receptor Neurological Disease
    Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP .
    Olcegepant
  • HY-15498
    Rimegepant
    5+ Cited Publications

    BMS-927711; BHV-3000

    		 CGRP Receptor Neurological Disease
    Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC50 of 8.01 and a Ki of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine .
    Rimegepant
  • HY-12366
    Ubrogepant

    MK-1602

    		 CGRP Receptor Cardiovascular Disease Neurological Disease
    Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
    Ubrogepant
  • HY-P1548
    β-CGRP, human
    1 Publications Verification

    human β-CGRP; CGRP-II (human)

    		 CGRP Receptor Cardiovascular Disease Inflammation/Immunology
    β-CGRP, human (Human β-CGRP) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells .
    β-CGRP, human
  • HY-10301
    MK-3207
    5 Publications Verification

    		 CGRP Receptor Neurological Disease
    MK-3207 is an orally active, highly selective and species-specific CGRP receptor antagonist (for human CGRP receptor: IC50=0.12 nM; Ki=0.024 nM). MK-3207 can be used for migraine studies .
    MK-3207
  • HY-P1471
    Adrenomedullin (AM) (22-52), human
    4 Publications Verification

    22-52-Adrenomedullin (human)

    		 CGRP Receptor Cardiovascular Disease
    Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .
    Adrenomedullin (AM) (22-52), human
  • HY-32709
    Telcagepant
    2 Publications Verification

    MK-0974

    		 CGRP Receptor Neurological Disease
    Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with Kis of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.
    Telcagepant
  • HY-10095A
    Olcegepant hydrochloride
    Maximum Cited Publications
    42 Publications Verification

    BIBN-4096 hydrochloride; BIBN4096BS hydrochloride

    		 CGRP Receptor Neurological Disease
    Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and with a Ki of 14.4 pM for human CGRP .
    Olcegepant hydrochloride
  • HY-P9938
    Erenumab
    1 Publications Verification

    AMG-334

    		 CGRP Receptor Neurological Disease
    Erenumab (AMG-334) is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .
    Erenumab
  • HY-P99017
    Eptinezumab

    ALD-403

    		 CGRP Receptor Neurological Disease
    Eptinezumab (ALD-403) is a human monoclonal antibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .
    Eptinezumab
  • HY-P1014
    HCGRP-(8-37)
    2 Publications Verification

    human α-CGRP (8-37)

    		 CGRP Receptor Cardiovascular Disease
    HCGRP-(8-37) (Human α-CGRP (8-37)) is a fragment of human calcitonin gene-related peptide (hCGRP) and an antagonist of the CGRP receptor, with an IC50 of 32.1 pM against the CGRP receptor. HCGRP-(8-37) blocks adenylate cyclase activation induced by CGRP receptor ligands and attenuates vascular responses triggered by CGRP. HCGRP-(8-37) reduces capsaicin-induced vasodilation in porcine nasal mucosa and superficial skin. HCGRP-(8-37) serves as a research tool to distinguish effects mediated by CGRP or calcitonin receptors, and to investigate CGRP-induced vascular effects .
    HCGRP-(8-37)
  • HY-P1770
    Adrenomedullin (16-31), human

    		CGRP Receptor Cardiovascular Disease
    Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesses pressor activity in the systemic vascular bed of the rat, but not the cat .
    Adrenomedullin (16-31), human
  • HY-P1548A
    β-CGRP, human TFA
    1 Publications Verification

    human β-CGRP TFA; CGRP-II (human) TFA

    		 CGRP Receptor Cardiovascular Disease Inflammation/Immunology
    β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells .
    β-CGRP, human TFA
  • HY-10302
    MK-3207 Hydrochloride
    5 Publications Verification

    		 CGRP Receptor Neurological Disease
    MK-3207 (Hydrochloride) is a potent and orally bioavailable CGRP receptor antagonist with IC50 of 0.12 nM and Ki of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.
    MK-3207 Hydrochloride
  • HY-117694
    MK-8825

    		CGRP Receptor Neurological Disease Inflammation/Immunology
    MK-8825 is an orally active, selective CGRP receptor antagonist with a Ki value of 47 pM for human CGRP receptors and 17 nM for rat CGRP receptors. MK-8825 blocks CGRP-stimulated cAMP responses and exhibits competitive-like antagonism. MK-8825 can be used in the research of migraine and temporomandibular joint disorders .
    MK-8825
  • HY-103304
    SB 268262

    		Others Neurological Disease
    CGRP antagonist 4 is an antagonist of calcitonin gene-related peptide (CGRP) receptor. CGRP antagonist 4 shows the highest affinity for CGRP receptors in the human brain. CGRP antagonist 4 can be used to study the binding properties of non-peptide calcitonin gene-related peptide (CGRP) receptor antagonist (gepants) in rat, pig and human menes .
    SB 268262
  • HY-12366R
    Ubrogepant (Standard)

    MK-1602 (Standard)

    		 CGRP Receptor Reference Standards Cardiovascular Disease Neurological Disease
    Ubrogepant (Standard) is the analytical standard of Ubrogepant. This product is intended for research and analytical applications. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
    Ubrogepant (Standard)
  • HY-P1548B
    β-CGRP, human acetate

    human β-CGRP acetate; CGRP-II (human) acetate

    		 CGRP Receptor Cardiovascular Disease Inflammation/Immunology
    β-CGRP, human acetate (Human β-CGRP acetate) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells .
    β-CGRP, human acetate
  • HY-32709S
    Telcagepant-d8

    MK-0974-d8

    		 Isotope-Labeled Compounds CGRP Receptor Neurological Disease
    Telcagepant-d8 (MK-0974-d8) is deuterium labeled Telcagepant. Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with Kis of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.
    Telcagepant-d8
  • HY-12366S
    Ubrogepant-d5

    MK-1602-d5

    		 Isotope-Labeled Compounds CGRP Receptor Cardiovascular Disease Neurological Disease
    Ubrogepant-d5 (MK-1602-d5) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .
    Ubrogepant-d5
  • HY-114574
    BMS-694153

    		CGRP Receptor Neurological Disease
    BMS-694153 is a potent antagonist of the human calcitonin gene-related peptide receptor (CGRP Receptor). BMS-694153 can be used for migraine with rapid and efficient intranasal exposure .
    BMS-694153
  • HY-P1471A
    Adrenomedullin (AM) (22-52), human TFA

    22-52-Adrenomedullin (human) TFA

    		 CGRP Receptor Cardiovascular Disease
    Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .
    Adrenomedullin (AM) (22-52), human TFA
  • HY-P1770A
    Adrenomedullin (16-31), human TFA

    		CGRP Receptor Cardiovascular Disease
    Adrenomedullin (16-31), human TFA is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human TFA possesses pressor activity in the systemic vascular bed of the rat, but not the cat .
    Adrenomedullin (16-31), human TFA
  • HY-10095R
    Olcegepant (Standard)

    BIBN-4096 (Standard); BIBN 4096BS (Standard)

    		 CGRP Receptor Reference Standards Neurological Disease
    Olcegepant (Standard) is the analytical standard of Olcegepant (HY-10095). This product is intended for research and analytical applications. Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP .
    Olcegepant (Standard)
  • HY-10302R
    MK-3207 hydrochloride (Standard)

    		Reference Standards CGRP Receptor Neurological Disease
    MK-3207 hydrochloride (Standard) is the analytical standard of MK-3207 hydrochloride (HY-10302). This product is intended for research and analytical applications. MK-3207 hydrochloride is a potent and orally bioavailable CGRP receptor antagonist with IC50 of 0.12 nM and Ki of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.
    MK-3207 hydrochloride (Standard)
  • HY-183180
    CGRP antagonist-8

    		CGRP Receptor Neurological Disease
    CGRP antagonist-8 is a CGRP receptor antagonist with an IC50 of 2.7 nM. CGRP antagonist-8 can be used for the research of migraine .
    CGRP antagonist-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: